About this item:

58 Views | 33 Downloads

Author Notes:

Tamar S. Polonsky, MD, MSCI, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC6080, Chicago, IL 60637. Email: tpolonsky@medicine.bsd.uchicago.edu

Disclosures: None.

Subjects:

Keywords:

  • diabetes
  • hypertension
  • obesity
  • primary prevention
  • risk factors

Highlights in ASCVD Primary Prevention for 2021

Tools:

Journal Title:

Journal of the American Heart Association

Volume:

Volume 11, Number 13

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

This review examines key studies published in 2021 that are related to primary prevention of atherosclerotic cardiovascular disease (ASCVD). Major randomized clinical trials (RCTs) concerning traditional risk factors or ASCVD events, meta‐analyses, and key observational studies related to primary prevention of ASCVD were considered. The review includes interventions for weight loss, cardiometabolic and renal disease, blood pressure control, diet, and the occurrence of cardiovascular disease events. A few studies considered both primary and secondary prevention populations. The review is not exhaustive. We did not include studies that focused on heart failure or clinical presentations that may be difficult to classify, such as acute or chronic ischemic cardiovascular disease without myocardial infarction. Our purpose was to highlight recent research that will help the reader stay abreast of the changing field of cardiovascular prevention.

Copyright information:

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/rdf).
Export to EndNote